Aptadir Therapeutics
Milan, Lombardy, Italy · Biotechnology, Genetics, Health Care
Aptadir Therapeutics is a preclinical biotech company developing a new class of RNA therapeutics. The company focuses on creating investigational RNA inhibitors for treating intractable genetic conditions. Their technology aims to block aberrant DNA methylation, potentially restoring normal gene expression and biological function. Aptadir is committed to advancing innovative therapies for genetic
Key facts
- Headquarters
- Milan, Lombardy, Italy
- Employees
- 4
- Industries
- Biotechnology, Genetics, Health Care
- Status
- Private
- Website
- aptadir.com
- Company page
Recent activity at Aptadir Therapeutics
Aptadir Therapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Sep 2026 | Seed | $45.0M |
Leadership
- Giovanni, Founder, Executive Chairman and CEO
- Marcin, Co-Founder
Verified email and direct lines for Aptadir Therapeutics’s decision-makers are on Fundz. See plans
Aptadir Therapeutics in the news
- APTADIR RAISES A €40M ($45M) SEED FINANCING TO ADVANCE FIRST-IN-CLASS DEMETHYLATING MEDICINES - GlobeNewswire (Sep 29, 2026)
- 4BIO Capital leads €40 Million ($45M) seed financing of - GlobeNewswire (Sep 29, 2026)
- CE-Ventures Backs Aptadir Therapeutics in €40 Million Seed Round, One of Europe’s Largest in Biotech - StreetInsider (Sep 29, 2026)
- Milan-based biotech Aptadir Therapeutics raises $45M seed round - Tech.eu (Sep 29, 2026)
- Launch of Aptadir Therapeutics With a Novel Class of RNA Inhibitors - BioSpace (Sep 24, 2024)
Companies similar to Aptadir Therapeutics
- MeiraGTx Holdings plc · Biotechnology, Genetics, Health Care, Therapeutics
- Gaomei Gene · Biotechnology, Genetics, Health Care, Therapeutics
- Crispr Therapeutics · Biotechnology, Genetics, Health Care, Therapeutics
- Florida Biotechnologies · Biotechnology, Genetics, Health Care, Therapeutics
- Freeline Therapeutics · Biotechnology, Genetics, Health Care, Therapeutics
About Aptadir Therapeutics: questions and answers
What does Aptadir Therapeutics do?
Aptadir Therapeutics is a preclinical biotech company developing a new class of RNA therapeutics. The company focuses on creating investigational RNA inhibitors for treating intractable genetic conditions. Their technology aims to block aberrant DNA methylation, potentially restoring normal gene expression and biological function. Aptadir is committed to advancing innovative therapies for genetic
Where is Aptadir Therapeutics headquartered?
Aptadir Therapeutics is headquartered in Milan, Lombardy, Italy.
How many employees does Aptadir Therapeutics have?
Aptadir Therapeutics has about 4 employees.
Has Aptadir Therapeutics raised funding?
Yes. Fundz has recorded 1 funding event for Aptadir Therapeutics. The most recent, Seed of $45.0M, was in Sep 2026.
Who leads Aptadir Therapeutics?
Giovanni is a Founder, Executive Chairman and CEO at Aptadir Therapeutics.
What is the latest news on Aptadir Therapeutics?
On Sep 29, 2026, Aptadir Therapeutics raises €40M ($45M) in Seed financing to advance first-in-class demethylating medicines, led by 4BIO Capital.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy